Blurbs

Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Keros Therapeutics (KROS) and Legend Biotech (LEGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAVResearch Report), Keros Therapeutics (KROSResearch Report) and Legend Biotech (LEGNResearch Report) with bullish sentiments.

Aravive (ARAV)

In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Aravive, with a price target of $26.00. The company’s shares closed last Wednesday at $0.80, close to its 52-week low of $0.58.

According to TipRanks.com, Hazlett is a 2-star analyst with an average return of -0.9% and a 36.7% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Paratek Pharmaceuticals, and Axsome Therapeutics.

Aravive has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, a 3150.0% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.

See the top stocks recommended by analysts >>

Keros Therapeutics (KROS)

BTIG analyst Julian Harrison reiterated a Buy rating on Keros Therapeutics on October 10 and set a price target of $95.00. The company’s shares closed last Wednesday at $42.97.

According to TipRanks.com, Harrison is a 1-star analyst with an average return of -8.5% and a 40.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Prometheus Biosciences, and Liquidia Technologies.

Currently, the analyst consensus on Keros Therapeutics is a Strong Buy with an average price target of $95.00, implying a 124.4% upside from current levels. In a report issued on October 10, Jefferies also reiterated a Buy rating on the stock with a $75.00 price target.

Legend Biotech (LEGN)

BMO Capital analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech today and set a price target of $77.00. The company’s shares closed last Wednesday at $38.83.

According to TipRanks.com, Biliouris is a 3-star analyst with an average return of 9.8% and a 31.3% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.

Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $69.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARAV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed